Levin V A, Phuphanich S, Liu H C, Da Silva V, Murovic J, Choucair A, Chamberlain M, Berger M, Seager M, Davis R L
Cancer Treat Rep. 1986 Nov;70(11):1271-4.
The Neuro-oncology Service of the University of California Brain Tumor Research Center conducted a nonrandomized phase II study to evaluate, in patients with recurrent malignant glioma, the benefit of a four-drug combination (BFHM) consisting of carmustine (1,3-bis (2-chloroethyl)-1-nitrosourea), 5-fluorouracil, hydroxyurea, and 6-mercaptopurine. There were 29 evaluable glioblastoma multiforme patients and 45 nonglioblastoma anaplastic glioma patients available for analysis. Tumor progression was analyzed as the primary study endpoint. Of the glioblastoma patients, 16 of 29 (55%) responded or stabilized on therapy; of the other anaplastic gliomas, 32 of 45 (71%) responded or stabilized. For patients who stabilized or responded to treatment, BFHM achieved a median time to tumor progression of 46 weeks with a 25th percentile time to tumor progression of 68 weeks for anaplastic gliomas and a median time to tumor progression of 23 weeks with a 25th percentile time to tumor progression of 36 weeks for glioblastoma multiforme patients. A Cox multivariate analysis demonstrated that age and Karnofsky score were important prognostic variables for these patients.
加利福尼亚大学脑肿瘤研究中心神经肿瘤服务部开展了一项非随机II期研究，以评估复发性恶性胶质瘤患者使用由卡莫司汀（1,3 - 双（2 - 氯乙基）-1 - 亚硝基脲）、5 - 氟尿嘧啶、羟基脲和6 - 巯基嘌呤组成的四联药物组合（BFHM）的获益情况。有29例可评估的多形性胶质母细胞瘤患者和45例非胶质母细胞瘤间变性胶质瘤患者可供分析。将肿瘤进展作为主要研究终点进行分析。在胶质母细胞瘤患者中，29例中有16例（55%）在治疗后有反应或病情稳定；在其他间变性胶质瘤患者中，45例中有32例（71%）有反应或病情稳定。对于病情稳定或对治疗有反应的患者，BFHM使间变性胶质瘤患者的肿瘤进展中位时间达到46周，第25百分位数的肿瘤进展时间为68周；使多形性胶质母细胞瘤患者的肿瘤进展中位时间达到23周，第25百分位数的肿瘤进展时间为36周。一项Cox多变量分析表明，年龄和卡诺夫斯基评分是这些患者重要的预后变量。
